Clinical trials: Peg-IFNα
Chronic Hepatitis B
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFNα in CHB patients
- Trial name
- HBV (NCT07135349)
- Testing
- BW-20507 with/without NUC, BW-20507 with/without NUC, Peg-IFNa
- Where
- 18 sites in China
- Volunteers
- 209 people
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.